Skip to main content
Premium Trial:

Request an Annual Quote

Burning Rock Biotech Lands $23.4M Series A+ Financing

NEW YORK (GenomeWeb) – Chinese personalized oncology firm Burning Rock Biotech announced last week that it has closed a CNY150 million ($23.4 million) Series A+ financing round led by Jifeng Capital, Sequioa Capital, and Legend Star.

The firm said in a statement that it would use the proceeds to fund research and development. Burning Rock offers next-generation sequencing-based cancer diagnostics and personalized treatment plants based on genetic testing.

Burning Rock received CNY62 million in Series A financing in 2014 from Northern Light Venture Capital and Legend Star.